SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Nutex Health Inc.
Date: April 22, 2025 · CIK: 0001479681 · Accession: 0000000000-25-004242

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-286554

Date
April 22, 2025
Author
Division of
Form
UPLOAD
Company
Nutex Health Inc.

Letter

Re: Nutex Health, Inc. Registration Statement on Form S-3 Filed April 15, 2025 File No. 333-286554 Dear Thomas T. Vo:

April 22, 2025

Thomas T. Vo Chief Executive Officer Nutex Health, Inc. 6030 S. Rice Ave., Suite C Houston, TX 77081

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Kate Beukenkamp at 202-551-3861 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Trade &
Services
cc: Gislar Donnenberg

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 22, 2025

Thomas T. Vo
Chief Executive Officer
Nutex Health, Inc.
6030 S. Rice Ave., Suite C
Houston, TX 77081

 Re: Nutex Health, Inc.
 Registration Statement on Form S-3
 Filed April 15, 2025
 File No. 333-286554
Dear Thomas T. Vo:

 This is to advise you that we do not intend to review your registration
statement.

 We request that you publicly file your registration statement at least
two business
days prior to the requested effective date and time. Please refer to Rules 460
and 461
regarding requests for acceleration. We remind you that the company and its
management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review,
comments, action or absence of action by the staff.

 Please contact Kate Beukenkamp at 202-551-3861 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Trade &
Services
cc: Gislar Donnenberg
</TEXT>
</DOCUMENT>